Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 5/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12662260 | 0.94 | STS (0.44) | STSNAMPTMAPTMMP13GPR119 | |
| SCHEMBL19065819 | 0.94 | STS (0.42) | STSNAMPTMAPTMMP13GPR119 | |
| SCHEMBL19082732 | 0.91 | STS (0.46) | STSMAPTMMP13GPR119NPBWR1 | |
| SCHEMBL22606389 | 0.91 | CXCR2 (0.41) | STSGPR119CXCR2 | |
| SCHEMBL12662153 | 0.89 | CXCR2 (0.49) | STSCXCR2 | |
| SCHEMBL17293460 | 0.88 | NAMPT (0.41) | STSNAMPTGPR119CXCR2 | |
| SCHEMBL2785669 | 0.85 | TGM2 (0.46) | STSMAPTGPR119 | |
| SCHEMBL19082747 | 0.85 | HSD11B1 (0.39) | STSMAPTGPR119CXCR2 | |
| SCHEMBL17293423 | 0.85 | HSD11B1 (0.39) | STSMAPTGPR119CXCR2 | |
| SCHEMBL17293424 | 0.85 | HSD11B1 (0.39) | STSMAPTGPR119CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3738956-A1 | CXCR2 ANTAGONIST | Medshine Discovery Inc. (CN) | 2020-11-18 | — | — | EP | disclosed |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-02 | — | — | US | disclosed |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-02 | — | — | US | disclosed |
| US-20190010135-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-10 | — | — | US | disclosed |
| US-10106515-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-23 | — | — | US | disclosed |
| EP-3148963-B1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-06-13 | — | — | EP | disclosed |
| EP-3148963-B1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-06-13 | — | — | EP | disclosed |
| US-20170224679-A1 | Use of CXCR2 Antagonists For The Prevention and/or Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| US-20170224679-A1 | Use of CXCR2 Antagonists For The Prevention and/or Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| US-20170224679-A1 | Use of CXCR2 Antagonists For The Prevention and/or Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | Glaxosmithline Intellectual Property Development Limited (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | Glaxosmithline Intellectual Property Development Limited (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | Glaxosmithline Intellectual Property Development Limited (GB) | 2017-07-06 | — | — | US | disclosed |
| EP-3174851-A1 | USE OF CXCR2 ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN) | GlaxoSmithKline Intellectual Property Management Limited (GB) | 2017-06-07 | — | — | EP | disclosed |
| EP-3148963-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2016016178-A1 | USE OF CXCR2 ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016016178-A1 | USE OF CXCR2 ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-02-04 | — | — | WO | disclosed |
| WO-2015181186-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015181186-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106515-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | STS 2835/4885NAMPT 2034/4885MAPT 3790/4885 |
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR3 | STS 3142/4885NAMPT 1827/4885MAPT 3694/4885 |
| US-20170224679-A1 | Use of CXCR2 Antagonists For The Prevention and/or Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) | CXCR2, CXCR3, CCR2 | STS 4044/4885NAMPT 498/4885MAPT 4699/4885 |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | STS 2838/4885NAMPT 2045/4885MAPT 3820/4885 |
| US-20190010135-A1 | Novel Compounds | CXCR2, CXCR1, CXCR3 | STS 3736/4885NAMPT 1345/4885MAPT 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.